Cadila Healthcare has received final approval to market Nifedipine extended-release tablets USP in the strengths of 30 mg, 60 mg, and 90 mg, from the US health regulator.

The tablet is used to treat high blood pressure and angina (chest pain brought on by exercise or stress). It has also received the final approval to market Cholestyramine for Oral Suspension USP, 4 g resin per pouch or scoopful. It is used together with a proper diet to lower cholesterol in the blood.

Read EquityPandit’s Technical Analysis of Nifty Pharma Outlook for the Week